Bruton tyrosine kinase inhibitors for multiple sclerosis

Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated worsening of disability, which is assumed to be mainly associated with transient infiltration of peripheral immune cells into the central nervous system (CNS). However, approved therapies are less effective at...

Descripción completa

Detalles Bibliográficos
Autores principales: Krämer, Julia, Bar-Or, Amit, Turner, Timothy J., Wiendl, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100639/
https://www.ncbi.nlm.nih.gov/pubmed/37055617
http://dx.doi.org/10.1038/s41582-023-00800-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100639/
https://www.ncbi.nlm.nih.gov/pubmed/37055617
http://dx.doi.org/10.1038/s41582-023-00800-7

Ejemplares similares